Hamostaseologie 2021; 41(03): 179-182
DOI: 10.1055/a-1369-3488

COVID-19: SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Rüdiger E. Scharf
1   Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, USA
2   Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA
3   Division of Experimental and Clinical Hemostasis, Hemotherapy, and Transfusion Medicine, and Hemophilia Comprehensive Care Center, Institute of Transplantation Diagnostics and Cell Therapy, Heinrich Heine University Medical Center, Düsseldorf, Germany
4   Division of Hematology and Central Hematology Laboratory, University Hospital of Lausanne, Lausanne, Switzerland
› Author Affiliations

Vaccination against SARS-CoV-2 is considered the most promising strategy to combat and control the COVID-19 pandemic. Consequently, highly effective vaccines have been developed with unprecedented speed, using distinct technologies such as messenger RNA-based products (with a lipid nanoparticle vehicle) or DNA-based vaccines (utilizing recombinant adenoviral chimpanzee or human vectors) both of which are encoding the SARS-CoV-2 spike glycoprotein. On the basis of randomized, blinded, controlled trials, the European Medicines Agency gave approval to four vaccines, including mRNA-BNT162b2 (BioNTech/Pfizer), mRNA-1273 (Moderna), ChAdOx1 nCov-19 (AstraZeneca), and Ad26.COV2.S (Johnson & Johnson/Janssen). The available vaccines have proven highly safe and effective.[1] Specifically, until very recently, no major safety warnings, other than exceedingly rare cases of anaphylaxis, were reported in initial trials. Moreover, the risk of serious adverse effects was demonstrated to be remarkably low following the vaccination of more than 400 million people worldwide.[2]

Publication History

Received: 25 May 2021

Accepted: 25 May 2021

Article published online:
30 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany